How Long Does Addiction Recovery Take? Timelines and Outcome Research

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

How Long Does Addiction Recovery Take? The Research-Based Answer

Addiction recovery can begin with meaningful changes in days or weeks, but building sustained remission, preventing recurrent harmful use, and restoring physical health, relationships, housing, work, and well-being often unfolds over months and years. The scientific literature supports no universal recovery deadline. A treatment episode may last weeks or months, medication treatment may continue for years, and progress in functioning may continue long after acute substance-related symptoms have improved. Clinical trajectories depend on substance, disorder severity, prior course, treatment access and continuity, physical and mental health, and the conditions in which a person lives. NIAAA, Support Recovery and SAMHSA, About Recovery describe recovery as an individualized, continuing process.

For practical planning, the first days to weeks often concern stabilization, immediate safety, withdrawal assessment, and initial engagement; subsequent months involve treatment response, changes in substance use, and rebuilding daily routines; follow-up over one or more years shows whether gains persist through changing life circumstances. These are overlapping observation windows, not universal stages. A person receiving methadone or buprenorphine for opioid use disorder may be doing very well in recovery while continuing medication. Someone who has stopped heavy drinking may meet clinical remission criteria while still working on sleep, mood, family trust, or finances. For long-term prognosis, the most informative question is which specific outcome is improving, over what period, and under what care conditions.

The evidence becomes misleading when a treatment program's advertised duration, a withdrawal timetable, a diagnostic threshold, and a claim about permanent recovery are treated as interchangeable. A 28-day residential stay is a period of service. Three months can be a meaningful clinical follow-up interval. One year can establish a sustained pattern in a particular study. Five years can describe a long-observed subgroup. None is a biological clock that automatically completes recovery.

What Researchers Mean by Recovery, Remission, and Outcomes

Substance use, disorder, and recovery are different measurements

Substance use refers to consumption of a psychoactive substance. Risky use concerns patterns associated with elevated probability of harm, while problematic use may cause consequences without necessarily meeting a formal diagnostic threshold. Substance use disorder is a clinical syndrome defined by a constellation of impaired control, consequences, risk, and physiological or behavioral features under specified criteria. Addiction is a clinical and scientific term often used for more severe compulsive patterns; it is not the name of every instance of substance use. Tolerance and physiological dependence can occur in medically supervised treatment without compulsive substance use disorder. Distinguishing these phenomena prevents changes in frequency of use from being mistaken for changes in the entire disorder.

Clinical remission denotes a reduction or absence of diagnostic symptoms according to a defined classification system and observation period. Recovery can additionally include health, functioning, safety, personal goals, and social participation. Abstinence means no use of the specified substance during the designated period; reduced or lower-risk use is a different outcome. Recurrence or return to substance use describes an event, while relapse is variably defined across studies, often referring to renewed problematic substance use or loss of an established improvement. The terms must be operationalized rather than assumed. For alcohol, NIAAA's research definitions deliberately combine remission from alcohol use disorder with cessation of heavy drinking and distinguish longer-term functioning.

Why a single recovery date cannot capture the process

A person can show marked improvement in intoxication-related risks while still experiencing craving. Sleep may improve on a different schedule from concentration or mood. Family relationships, housing security, occupational functioning, and financial stability may improve through independent processes. Thus a recovery timeline is better understood as a group of related trajectories rather than a single event. SAMHSA identifies health, home, purpose, and community as major dimensions of recovery; these domains help explain why a strictly symptom-based endpoint captures only part of the experience. SAMHSA, 2024.

Even among studies that use the same word, definitions diverge. Some report time to first month without a substance; others measure six months without heavy drinking, one year without DSM symptoms, days in treatment, drug-testing results, fewer emergency visits, survival, patient-defined recovery, or quality-of-life scores. A claim that a study found recovery at six months is therefore incomplete until its outcome and population are specified. Research on alcohol-related recovery supports the need to measure both substance use and broader health rather than reducing clinical success to one variable. NIAAA, Recovery Overview.

A Clinically Useful Timeline: Days, Weeks, Months, and Years

Initial days and weeks: safety, engagement, and early response

The initial period may include medical evaluation of intoxication and withdrawal, assessment of co-occurring psychiatric and physical conditions, treatment engagement, overdose prevention, and support for practical needs. Withdrawal symptoms may resolve within a relatively short period for some substances, but their resolution does not establish remission or a stable recovery trajectory. Alcohol and benzodiazepine withdrawal can become life-threatening; supervised assessment is essential for people with physiological dependence or significant withdrawal risk. Opioid withdrawal and overdose are distinct syndromes with different emergency needs. A calendar-based self-detoxification plan is inappropriate when medical risks are present.

Early changes matter because immediate safety and continued contact with care can influence later outcomes. A first appointment, a successful medication start, fewer heavy drinking days, or a reduction in exposure to overdose hazards can constitute meaningful progress before longer-term recovery indicators are available. For a person with opioid use disorder, receiving evidence-based medication is itself an active treatment phase, not a pause before recovery begins. CDC, Treating Opioid Use Disorder.

First one to three months: learning what treatment response looks like

Over the next weeks and months, clinicians can examine whether a plan is feasible and whether symptoms, substance use, functioning, and risk are moving in a favorable direction. Repeated visits allow treatment to be adjusted when cravings remain severe, medication is difficult to access, or new social pressures arise. Support may include appropriate medication, behavioral treatment, mutual-help participation, recovery housing, case management, or other individualized services. The presence of an ongoing need is not evidence of personal failure; it is information for clinical reassessment.

The traditional claim that at least 90 days of treatment is necessary comes from findings about treatment exposure and outcomes, especially older residential and outpatient treatment studies. NIDA's Principles of Drug Addiction Treatment reports that participation for less than 90 days in those settings generally has limited effectiveness, while longer engagement is associated with better outcomes. This is a research-based service-planning principle, not a rule that everyone is recovered after 90 days, that every intervention must last precisely that long, or that all types of care have equal duration requirements. The same guidance notes that medication maintenance may extend much longer. NIDA, Principles of Drug Addiction Treatment.

Three to twelve months: consolidation and changing exposure to risk

Across this interval, progress may involve fewer or less severe episodes of substance use, diagnostic improvement, consistent medication access, stronger coping strategies, more reliable housing, and restoration of work or school roles. The first year may involve gains in some areas and continuing distress in others. NIAAA describes alcohol recovery as involving changes in craving, negative emotion, sleep, self-efficacy, and life satisfaction; some well-being measures can begin improving later than initial drinking outcomes. The available evidence shows variation rather than a guaranteed point at which cravings or mood symptoms disappear. NIAAA, Support Recovery.

Follow-up is important even when early progress is strong. A person may be stable in a highly structured environment but encounter different demands following discharge, a change of housing, workplace stress, family conflict, or discontinuation of treatment. Longitudinal research should distinguish improvement while engaged in services from outcomes after services change. It should also distinguish substance-use recurrence from a return to diagnosable disorder.

One year to several years: sustained outcomes and functioning

Longer observation is needed to understand sustained remission and the capacity to maintain improvements across major life changes. Medical comorbidities, chronic pain, psychiatric symptoms, vocational rebuilding, and social functioning may require continuing attention. Importantly, some people reach stable remission without repeated formal treatment, others benefit from intermittent episodes, and others need continuous clinical care. The course may differ substantially even among people with the same primary substance.

In a longitudinal cohort of 1,271 people admitted to publicly funded treatment in one US metropolitan area, Dennis and colleagues found that 47% had achieved at least a year of abstinence during the three years after study intake. Survival-analysis estimates of the interval from first substance use to last use and from first treatment to last use were much longer, with medians of 27 and nine years respectively. These estimates reflect a selected, multiply affected treatment sample with retrospective histories and specific definitions. They do not imply that the typical person needs nine years of treatment, that recovery begins only after decades, or that these medians describe the modern population. Dennis et al., 2005.

Five years and beyond: long-term stability is an observation, not a deadline

The often repeated notion that recovery is 'complete' after five years conflates long-run risk observations with a clinical definition. Some research and service traditions treat several years of sustained remission as a marker of greater stability. But risk varies by prior severity, type of substance, treatment access, definition of recurrence, and life circumstances. A five-year milestone can be meaningful to individuals and research programs without providing a universal guarantee of lifetime abstinence, absence of risk, or restoration of all functioning.

For alcohol, NIAAA's research framework explicitly defines several duration bands, including more than five years for 'stable' remission or cessation of heavy drinking. These are measurement conventions used for alcohol outcomes, not biological transition points that automatically apply to opioids, stimulants, cannabis, or every person. NIAAA, Recovery Research Definitions. Long-term recovery deserves ongoing attention to health and participation rather than automatic dismissal of possible new care needs.

What Longitudinal Studies Actually Show

Treatment cohorts are not the whole population

People who enter publicly funded, specialized, or residential treatment often differ from those who resolve problems without such services. Treatment cohorts may contain greater clinical severity, psychiatric comorbidity, socioeconomic adversity, or repeated previous episodes. Their outcome distributions cannot simply be generalized to everyone who has ever experienced a drug or alcohol problem. Conversely, retrospective surveys of people who already resolved a problem can miss those who died, are still struggling, or never defined their experiences using the survey's wording.

A probability-based national survey reported that 9.1% of US adults had resolved what they considered a significant past alcohol or other drug problem; among those reporting resolution, 53.9% described having used an assisted pathway. The study shows diverse paths toward resolution, including professional and nonprofessional pathways. It does not measure the treatment success rate for all currently diagnosed patients or establish which pathway would work for a given individual. Kelly et al., 2017.

The number of recovery attempts has a skewed distribution

In a national study of US adults who reported having resolved a significant alcohol or drug problem, the mean number of serious recovery attempts was 5.35, the median was two, and the modal response was one. Extreme responses pulled the mean upward. Reporting the mean alone as 'the average person needs five attempts' conceals that distribution; reporting the median alone likewise conceals a subgroup with many more attempts. The cohort includes people who already reported successful problem resolution and cannot establish the future number of attempts needed by a currently ill person. Kelly et al., 2019.

An 'attempt' may also be defined retrospectively and differently by respondents. Attempts to change without treatment, treatment episodes, and discrete recurrence events are not the same denominator. A person can receive several kinds of care during one sustained recovery effort. Counting episodes without describing their clinical context can exaggerate or minimize what actually happened.

Long follow-up does not mean every participant stays on one path

Moos and Moos followed 461 initially untreated help-seeking participants with alcohol use disorders at several time points extending to 16 years. People who did not obtain assistance were less likely to reach remission at three years and more likely to report later relapse than people who obtained help, after accounting for studied baseline variables. The findings also connected later course to drinking severity, self-efficacy, and coping. The observational design permits associations, not a causal estimate that any particular person's outcome would necessarily have changed by receiving one specific service. Moos and Moos, 2006.

A common interpretation error is to assume that the number of people in remission at a later wave equals the number who remained continuously remitted since baseline. Some participants move between remission and renewed symptoms. Others may become unreachable, experience serious illness, or die. A credible recovery-timeline study needs to describe transitions and account for attrition, competing risks, and variable observation periods.

Why There Is No Single Recovery Duration Across Substances

Alcohol use disorder

Alcohol recovery research can measure heavy drinking, diagnostic symptoms, abstinence, health consequences, and functioning separately. Medication and psychosocial treatment can support changes in drinking outcomes, while broader physical and psychological improvement may extend beyond initial reduction in use. NIAAA's clinical synthesis states that many people reduce or resolve alcohol problems over time, and that some alcohol-related brain changes improve with months of abstinence. The course of cognitive, sleep, and affective recovery is heterogeneous; severe damage or co-occurring conditions may leave persistent difficulties. NIAAA, AUD From Risk to Recovery and NIAAA, Neuroscience.

Early recognition of serious alcohol withdrawal risk is a separate clinical priority. Withdrawal seizures, delirium, marked confusion, hallucinations with autonomic instability, or worsening medical symptoms need urgent professional attention. A reduction in drinking that occurs safely in one person cannot justify unsupervised abrupt cessation in another person with physiological dependence.

Opioid use disorder

For opioid use disorder, outcomes must incorporate survival and overdose prevention alongside abstinence, illicit opioid use, functional recovery, and treatment retention. Methadone and buprenorphine may be continued for years when they are effective and clinically appropriate. Remaining on medication does not mean recovery has failed. A large systematic review and meta-analysis found lower all-cause mortality during opioid agonist treatment than outside treatment; the pooled rate ratio across cohort studies was 0.47 (95% confidence interval 0.42 to 0.53). This observational pooled estimate is highly relevant to planning ongoing care, but it is not an individual causal probability and should be interpreted with the study designs' limitations. Santo et al., 2021.

The risk of opioid overdose can rise after a period of reduced exposure and lost tolerance if use resumes. Discontinuation of treatment therefore requires careful shared planning; stopping medication simply because a fixed number of months has passed can jeopardize progress. Naloxone access and emergency response education are components of safety at every stage of care. CDC, Overdose Prevention.

Stimulant use disorders

Cocaine and methamphetamine problems can involve cycles of use, craving, sleep disruption, psychiatric symptoms, and social adversity. Improvement timelines differ according to pattern of use, complications, and treatment engagement. The strongest established behavioral evidence for stimulant use disorder includes contingency management; the ASAM and AAAP guideline addresses its use and the management of co-occurring conditions. This evidence supports care planning but does not identify an identical number of weeks for remission across all stimulant-using groups. ASAM and AAAP, Clinical Practice Guideline.

Chest pain, severe agitation, hyperthermia, seizures, acute psychosis, or suspected stroke during or after stimulant use require emergency medical evaluation. These are acute safety problems and should not be interpreted as ordinary recovery discomfort.

Cannabis, nicotine, benzodiazepines, and polysubstance use

Cannabis use disorder, tobacco use disorder, benzodiazepine-related problems, and combined substance use differ in pharmacology, withdrawal manifestations, available evidence-based medications, clinical severity, and environmental exposures. Timing estimates should arise from the relevant disorder and outcome; a timetable derived from alcohol treatment cannot be transferred wholesale to cannabis or nicotine. Prescribed benzodiazepine physiological dependence should be clinically distinguished from benzodiazepine use disorder, and abrupt discontinuation after sustained use can produce dangerous withdrawal. For people using several substances, interactions and overlapping withdrawal syndromes can complicate evaluation and require coordinated care.

Smoking cessation may be followed by substantial health benefits while craving or habit-linked responses continue. Benzodiazepine tapering may need individualized medical supervision extending beyond a short program. Different forms of improvement can coexist within a longer recovery trajectory. The proper measure remains longitudinal clinical status and functioning, not an assumed standard duration.

Does Longer Treatment Improve Long-Term Outcomes?

Treatment length is a feature of a care plan, not proof of success on its own. If people with greater severity remain in care longer, a naïve comparison of short and long programs can make extended treatment appear worse or better for reasons unrelated to treatment effect. People who remain engaged may also have more resources, motivation, or continuity of access. Good research should account for baseline differences, dropout, study design, and what treatment actually consisted of.

A meta-analysis of 33 controlled trials found a small but statistically significant benefit of continuing care after more intensive initial treatment, including effects at follow-up. The estimate supports ongoing services for many patients but does not mean every type of continuing care is equally effective. Blodgett et al., 2014. A separate systematic review and meta-analysis of planned long-term treatment or support lasting at least 18 months found a favorable pooled association with abstinence or moderate consumption compared with shorter standard care (unadjusted odds ratio 1.347, 95% CI 1.087–1.668). Variation in programs and participants constrains direct translation to an individual prescription for 18 months. Long-term treatment meta-analysis, 2021.

Sustained opioid agonist treatment illustrates the danger of using a generic short-program target. Outcomes include continuing protection from overdose and reduction in mortality. Retention itself is a health-service outcome, though not a complete measure of quality of life or freedom from substance-related problems. Systematic reviews find wide variation in opioid treatment retention across settings and follow-up periods. Comparisons should report time, medication and setting, and reasons for discontinuation rather than treating all dropout as equivalent. Retention systematic review and Santo et al., 2021.

Residential care, outpatient psychotherapy, medication management, primary-care follow-up, recovery housing, and peer support are different interventions. The best duration and setting depend on current safety, clinical severity, preferences, response, practical access, and the need for continuity. A 2025 systematic review of recovery housing included five eligible comparative studies, suggesting improvements in some abstinence and socioeconomic outcomes while emphasizing a small and heterogeneous evidence base. Housing support may affect recovery conditions, yet these findings cannot prove an ideal duration of residence. Vilsaint et al., 2025.

Why People Recover at Different Rates

Disorder severity, early onset, and co-occurring illness

Higher severity, previous complications, early onset, repeated episodes, and co-occurring mental health conditions can be associated with a more complicated course. Association does not determine an individual's outcome, and its direction may change after adjustment for access to care and social circumstances. The Dennis clinical cohort, for example, found longer estimated time to a year of abstinence in subgroups with earlier substance-use onset and greater mental distress. Because the sample was drawn from treatment entrants, these findings describe risk within that setting, not a definitive recovery prediction for the general public. Dennis et al., 2005.

Depression, anxiety, trauma-related symptoms, psychosis, pain, sleep disorders, and suicide risk may require coordinated assessment. Symptoms arising from withdrawal or intoxication should be evaluated alongside independent psychiatric disorders. If serious depression, psychosis, or suicidal thinking is present, care should address both immediate safety and longer-term treatment rather than postponing mental health needs until an arbitrary sobriety milestone.

Recovery capital and continuity of everyday life

Stable housing, safety, transportation, financial resources, family relationships, meaningful work, and access to care can shape opportunities to maintain progress. These are commonly discussed as recovery capital. A person may have strong motivation and effective medication yet struggle when appointments are inaccessible or living conditions repeatedly expose them to risk. Population-level correlations should not be treated as moral judgments about an individual's commitment. SAMHSA, About Recovery.

Work and education are also outcomes in their own right. A 2024 scoping review of 33 studies described diverse trajectories involving education, employment, and career functioning in recovery; the evidence is useful for recognizing wider recovery domains but is not a direct experiment measuring how many months substance use disorder takes to resolve. Maynes and Grant, 2024.

Social context, identity, and access to effective services

Stigma, discrimination, unstable income, insurance barriers, criminal-legal involvement, caregiving demands, and availability of culturally appropriate treatment can affect time to care and continuity. Adolescents, pregnant people, older adults, and people with major medical illness need age- and circumstance-specific assessment. Population averages should not substitute for individualized care, especially when study samples exclude people with substantial complexity or underrepresent certain groups.

Early improvement can produce new challenges: returning to work, repairing relationships, renegotiating family boundaries, or managing a long-avoided mental health condition. Such work may make recovery feel slower even while harmful substance-related behavior is diminishing. Tracking multiple outcomes permits clinical teams and people in recovery to recognize genuine progress without masking ongoing risks.

Recurrence, Setbacks, and the Meaning of Time Since Last Use

A recurrence of use after improvement is a clinical signal to reassess exposure, supports, medications, safety, and care fit. It need not erase preceding changes in health or functioning. At the same time, recurrence after reduced tolerance may be medically dangerous, particularly with opioids. The significance of a single use event varies according to substance, dose, pattern, situation, overdose exposure, and the person's treatment goals. Reliable reporting requires a clear distinction between any use, heavy use, loss of diagnostic remission, and clinical deterioration.

The timing of renewed symptoms can be especially informative around transitions: discontinuation of medication, leaving residential treatment, changes in housing, bereavement, or new medical complications. Many studies are built around discharge or intake rather than the patient's own recovery start, and that affects how their curves should be read. A return to use at a measured interval does not license a blanket conclusion about lifelong outcome. Longitudinal follow-up and rapid reengagement with care are more useful than all-or-nothing labels.

Why 'five years to be safe' is an overstatement

The probability of recurrence generally depends on the duration and quality of past stability, but figures drawn from specific historical cohorts or different diagnostic conditions should not be turned into a universal five-year risk threshold. NIAAA's greater-than-five-year 'stable' category is a research classification for alcohol outcomes. A statistical risk may decrease across time even when no sharp discontinuity occurs at the anniversary. Individuals may also face fresh risk because of changing health or circumstances. NIAAA recovery definitions.

A more defensible question for follow-up is whether the person has a workable safety and continuity plan, access to evidence-based care, progressively improving functioning, and a way to address renewed symptoms early. Calendar milestones may help people recognize achievements while care remains matched to actual needs.

How to Evaluate Progress Without a False Countdown

An effective clinical progress review distinguishes a baseline, the interval since the last review, and current functioning. Depending on the disorder, the team may monitor diagnostic symptoms, days of use or heavy use, intoxication and overdose events, medication adherence and tolerability, cravings, sleep, mood, relationships, housing, and participation in meaningful activities. Biological tests can inform a specific clinical question but cannot independently measure recovery identity or social well-being. Self-reported goals and experiences remain important alongside measurable clinical indicators.

Progress can be visible before full remission. Fewer episodes of risky use, sustained medication engagement, improved sleep, fewer emergency presentations, or reliable participation in care may be meaningful interim changes. A plan may need adaptation when adverse effects appear, repeated use persists, or functioning worsens. Screening instruments identify a possible need for further evaluation; diagnostic assessment determines whether a disorder is present and how its course should be described. Neither should be replaced by a sobriety-day counter.

Research outcomes should specify the denominator. Does an improvement percentage count all enrolled patients, only those retained in care, or only those reached at follow-up? Were deaths counted? Did the study measure continuous abstinence or a recent 30-day window? Was the start date first use, first treatment, discharge, or the first reported remission? These details often explain why apparently conflicting recovery statistics can both be correct within their original contexts.

What the Evidence Establishes and What Remains Uncertain

Established findings support the possibility of substantial recovery after serious substance-related problems, considerable variation across people and settings, the value of effective substance-specific treatment, and the relevance of continued support. Evidence is especially strong that opioid agonist treatment is associated with lower mortality while patients receive it, and that selected evidence-based interventions can improve substance-use outcomes. Sustained recovery is a legitimate goal at every stage, not something reserved for people who achieve an arbitrary treatment-free interval. Santo et al., 2021; NIAAA, AUD recovery.

Evidence is more limited for a single typical number of months to 'complete' recovery. Studies vary in diagnostic systems, substances, baseline severity, definitions, interventions, socioeconomic conditions, and follow-up completeness. Retrospective surveys introduce recall and survivor selection. Treatment-seeking cohorts introduce clinical selection. Follow-up attrition can bias apparent long-term success when participants with poorer outcomes are harder to reach. An intervention associated with longer retention does not, by itself, demonstrate that retention caused every observed improvement.

The strongest scientific use of recovery timelines is therefore comparative and conditional: describing outcomes for a defined population, clinical endpoint, and follow-up duration, with explicit uncertainty. The evidence does not sustain an individual countdown, a standard five-year cure date, or the claim that a return to use makes all previous recovery invalid.

Clinical Safety: When the Timeline Must Yield to Immediate Care

People with severe alcohol or benzodiazepine physiological dependence should seek professional advice before abruptly stopping or sharply reducing use. Confusion, seizures, severe tremor with instability, hallucinations, or deterioration during withdrawal demand urgent medical evaluation. People using opioids face overdose risk even after a period of abstinence; loss of tolerance makes resuming previous amounts particularly hazardous. If someone is unresponsive or breathing slowly or irregularly after possible opioid exposure, seek emergency services immediately and administer naloxone if available, following local emergency guidance. CDC, 5 Things to Know About Naloxone.

Severe stimulant-associated chest pain, high fever, seizures, or psychosis require emergency assessment. Suicidal intent, inability to remain safe, severe confusion, and serious medical complications warrant immediate professional help regardless of where someone believes they are on a recovery timeline. Pregnant patients, adolescents, people with complex medical problems, and those combining sedatives, alcohol, or opioids need individualized clinical planning. Ongoing prescribed treatment should not be stopped solely to meet a recovery anniversary.

Frequently Asked Questions

Can addiction recovery happen in thirty days?

Some people experience substantial early benefits in thirty days: fewer intoxication-related harms, engagement with care, better routines, or initial abstinence. Thirty days is far too narrow a window to certify stable remission or durable recovery in everyone. Outcomes must be assessed according to disorder, safety, and the goals being measured.

Is ninety days enough for addiction recovery?

Ninety days can provide a valuable treatment and follow-up interval. Historical NIDA guidance associates shorter residential or outpatient treatment participation with poorer outcomes in the studied settings. Ninety days does not define a universal endpoint, and medication treatment or continuing care may be appropriate for far longer. NIDA treatment principles.

Does the first year determine the rest of recovery?

The first year is clinically important and may involve substantial progress and setbacks. Long-term cohorts document later improvement as well as later recurrence. A difficult first year does not establish an individual's lifetime prognosis; nor does an easy first year guarantee that future support will never be useful. Moos and Moos, 2006.

Is recovery complete after five years of abstinence?

Five years of stability may be meaningful and is used as a research threshold in some alcohol outcome definitions. It does not guarantee that every domain of functioning is fully restored or that all future substance-related risk is zero. The five-year point is a convention and historical marker, not a universal cure mechanism. NIAAA recovery definitions.

Does taking buprenorphine or methadone mean a person is still addicted?

Appropriately prescribed opioid agonist medication is an evidence-based treatment. Physiological adaptation to a medication is different from uncontrolled harmful use. Effective ongoing medication can coexist with recovery, improved function, and reduced mortality risk. No standard timeline requires discontinuation of these medications to count as recovery. CDC, Treating Opioid Use Disorder and Santo et al., 2021.

How many attempts does successful recovery usually take?

Among US adults surveyed after resolving a significant alcohol or drug problem, the most frequent answer was one serious attempt and the median was two, with a strongly skewed distribution and much larger counts for some respondents. That retrospective distribution does not predict any current patient's future attempts. Kelly et al., 2019.

What is a realistic long-term plan?

A realistic plan starts with medically appropriate assessment, immediate safety, effective substance-specific treatment, achievable goals, and scheduled reassessment. It includes a way to maintain treatment when useful, address housing and family needs, monitor co-occurring conditions, and reconnect rapidly if risks increase. The plan can change with clinical response; its success is evaluated through health, functioning, and meaningful outcomes rather than the number printed on a program brochure.

Conclusion

Addiction recovery takes different amounts of time because recovery is a collection of related clinical, behavioral, social, and health processes. Meaningful changes can begin in the first weeks, remission and treatment response can develop over months, and durable stability or broader restoration of life functioning may evolve over several years. Longitudinal cohort research describes widely distributed outcomes, while controlled trials and systematic reviews support continuing effective care for many people. The best evidence-based timeline identifies the substance, the clinical endpoint, the observation period, and the resources available to sustain progress. Recovery is assessed by the life a person is able to live safely and meaningfully, together with measurable changes in the disorder.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — The comprehensive scientific chapter and verified research-cluster context.

Can Substance Use Disorder Go Into Remission? Diagnosis and Prognosis — Diagnostic remission and prognostic concepts, distinct from personal recovery duration.

Substance Use Disorders and Suicide Risk: Evidence, Assessment, and Safety — Clinical risk evaluation and immediate safety during substance-related problems.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — Co-occurring anxiety, withdrawal-related symptoms, and care implications.

References

American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). Clinical Practice Guideline on the Management of Stimulant Use Disorder. Source

Beaulieu, M., Tremblay, J., Baudry, C., Pearson, J., and Bertrand, K. (2021). A systematic review and meta-analysis of the efficacy of the long-term treatment and support of substance use disorders. Social Science and Medicine, 285, 114289. Source

Blodgett, J. C., Maisel, N. C., Fuh, I. L., Wilbourne, P. L., and Finney, J. W. (2014). How effective is continuing care for substance use disorders? A meta-analytic review. Journal of Substance Abuse Treatment. PubMed.

Centers for Disease Control and Prevention. (2024). 5 Things to Know About Naloxone. Official resource.

Centers for Disease Control and Prevention. (2024). Opioid Use Disorder: Treating. Official resource.

Centers for Disease Control and Prevention. (n.d.). Preventing Opioid Overdose. Source

Dennis, M. L., Scott, C. K., Funk, R., and Foss, M. A. (2005). The duration and correlates of addiction and treatment careers. Journal of Substance Abuse Treatment, 28(Suppl 1), S51–S62. DOI.

Kelly, J. F., Bergman, B. G., Hoeppner, B. B., Vilsaint, C. L., and White, W. L. (2017). Prevalence and pathways of recovery from drug and alcohol problems in the United States population. Drug and Alcohol Dependence, 181, 162–169. DOI.

Kelly, J. F., Greene, M. C., Bergman, B. G., and colleagues. (2019). How many recovery attempts does it take to successfully resolve an alcohol or drug problem? Alcoholism: Clinical and Experimental Research, 43, 1533–1544. DOI.

Maynes, T. D., Grant, E. K., and colleagues. (2024). The career trajectories and outcomes in substance use recovery: A scoping review. Journal of Career Development. DOI.

McKay, J. R. (2021). Impact of continuing care on recovery from substance use disorder. Alcohol Research: Current Reviews. DOI.

Moos, R. H., and Moos, B. S. (2006). Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction, 101, 212–222. DOI.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). Alcohol Use Disorder: From Risk to Diagnosis to Recovery. Official resource.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). Neuroscience: The Brain in Addiction and Recovery. Official resource.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). NIAAA Recovery Research Definitions. Official resource.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). Recovery from Alcohol Use Disorder: Overview. Source

National Institute on Alcohol Abuse and Alcoholism. (n.d.). Support Recovery: It's a Marathon, Not a Sprint. Official resource.

National Institute on Drug Abuse. (2014). Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition). Official PDF.

O'Connor, A. M., Cousins, G., Durand, L., Barry, J., and Boland, F. (2020). Retention of patients in opioid substitution treatment: A systematic review. PLOS ONE, 15(5), e0232086. Source

Santo, T., Jr., Clark, B., Hickman, M., and colleagues. (2021). Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis. JAMA Psychiatry, 78, 979–993. DOI.

Substance Abuse and Mental Health Services Administration. (2024). About Recovery. Official resource.

Vilsaint, C. L., Tansey, A. G., Hennessy, E. A., Eddie, D., Hoffman, L. A., and Kelly, J. F. (2025). Recovery housing for substance use disorder: A systematic review. Frontiers in Public Health, 13. DOI.